New probiotic clones have been obtained having enhanced activity against Helicobacter pylori infection. The new clones are derived from selected strains of Lactobacillus acidophilus and Bifidobacterium animalis lactis sp. They are advantageously non-susceptible to antibiotics currently used in the treatment of Helicobacter pylori infection, which makes them ideal for co-treatment with said antibiotics in the eradication of Helicobacter pylori infection. Synergistic effects of combinations among the present probiotics and their strong adjuvant effect on the activity of antibiotics on Helicobacter pylori are herein reported.

Evolved strains of Bifidobacterium and Lactobacillus are provided. The evolved strains have probiotic properties and have enhanced storage stability in both wet and dry conditions. The strains of the invention contain key genetic mutations and phenotypic alterations as compared with wild-type.

A probiotic for inhibiting and preventing the progression of a renal disease and a composition containing the same are disclosed. The probiotic contains a novel Lactobacillus acidophilus BP105 strain, a novel Lactobacillus salivarius BP121 strain. The novel probiotics, the Lactobacillus acidophilus BP105 strain and the Lactobacillus salivarius BP121 strain exhibit excellent indoxyl sulfate removal ability, p-cresol removal ability, and phosphorus absorption ability.

A method and system for the treatment of Monarch butterflies (Danaus plexippus Kluk (Lepidoptera: Nymphalidae) to protect them from various life-threatening conditions, including the negative effects of various pesticides, provides Monarch butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil. Certain embodiments involve the inoculation of flowers by honey bees with desired bacteria that are able to degrade pesticides, such that when Monarch butterflies visit such flowers, they are exposed to such bacteria, transforming the microbiome of the Monarch butterflies so that pesticides can be degraded, thus enhancing the health of the Monarch butterflies.

This invention relates to the use of Bacillus amyloliquefaciens and/or Bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions for use in the prevention and/or treatment of inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, indeterminate colitis and microscopic colitis, the compositions thus obtained, and a method for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions for use in the prevention and/or treatment of inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, indeterminate colitis and microscopic colitis.

A feed including cashew nut shell liquid and bacterial cells is provided for raising non-human monogastric animals such as chickens or pigs, wherein the cashew nut shell liquid content is not more than 500 ppm by mass with respect to the total amount of the feed. The feed can stimulate weight gain in non-human monogastric animals such as chickens or pigs and increase the efficiency in, for example, meat production.

The present invention provides a lactic acid bacteria composition, which comprises: a Lactobacillus plantarum PL-02 strain, a Lactobacillus acidophilusTYCA06 strain, a Lactobacillus casei CS-773 strain, and a physiologically acceptable excipient, diluent, or carrier. All of the strains are deposited at the China General Microbiological Culture Collection Center.

The invention relates to the use of a Streptococcus thermophilus strain with a deficiency in glucose metabolism for improving growth of a Lactobacillus strain in a process for producing a fermented milk product.

The present invention relates to the strain of Lactobacillus plantarum NCIMB 43029, the strain of Lactobacillus acidophilus NCIMB 43030, a composition with both antibacterial and re-epithelializing action which includes Lactobacillus plantarum and Lactobacillus acidophilus and optionally Streptococcus thermophilus and/or Bacillus amyloliquefaciens intended to be used as a medicament for the re-epithelialisation of lesions or wounds, a bandage comprising said composition and kits comprising such a composition.

Disclosed are probiotic formulations comprising fortified avian eggs and avian egg products such as egg powder, and methods for producing the same substantially no meat containing growth media such as MRS. The formulations may be used to supplement food that include, but are not limited to, baby foods, milk, and pet foods. Effective amounts of the fortified egg formulations comprising at least about 10.sup.9 CFU/dosage of probiotics may be used to treat health issues that include, but are not limited to, irritable bowel syndrome. The probiotic formulation may comprise bacterial strains comprising at least one of L. casei, L. rhamnosus, B. breve, Bifidobacterium longum, L. acidophilus, L. plantarum, B. bifidum, L. fermentum, L. lactis, L. paracasei, and L. salivarius.